Division of Cardiovascular Medicine, Department of Medicine, Stanford University, CA (S.-P.L., E.A.A., M.V.P.).
Department of Internal Medicine, Seoul National University Hospital, South Korea (S.-P.L.).
Circ Heart Fail. 2018 Sep;11(9):e005191. doi: 10.1161/CIRCHEARTFAILURE.118.005191.
Background Although atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) patients, the relationship between genetic variation and AF has been poorly defined. Characterizing genetic subtypes of HCM and their associations with AF may help to improve personalized medical care. We aimed to investigate the link between sarcomeric gene variation and incident AF in HCM patients. Methods and Results Patients from the multinational Sarcomeric Human Cardiomyopathy Registry were followed for incident AF. Those with likely pathogenic or pathogenic variants in sarcomeric genes were included. The AF incidence was ascertained by review of medical records and electrocardiograms at each investigative site. One thousand forty adult HCM patients, without baseline AF and with likely pathogenic or pathogenic variation in either MYH7 (n=296), MYBPC3 (n=659), or thin filament genes (n=85), were included. Compared with patients with variation in other sarcomeric genes, those with MYH7 variants were younger on first clinical encounter at the Sarcomeric Human Cardiomyopathy Registry site and more likely to be probands than the MYBPC3 variants. During an average follow-up of 7.2 years, 198 incident AF events occurred. Patients with likely pathogenic or pathogenic mutations in MYH7 had the highest incidence of AF after adjusting for age, sex, proband status, left atrial size, maximal wall thickness, and peak pressure gradient (hazard ratio, 1.7; 95% CI, 1.1-2.6; P=0.009). Conclusions During a mean follow-up of 7.2 years, new-onset AF developed in 19% of HCM patients with sarcomeric mutations. Compared with other sarcomeric genes, patients with likely pathogenic or pathogenic variation in MYH7 had a higher rate of incident AF independent of clinical and echocardiographic factors.
背景 尽管心房颤动(AF)在肥厚型心肌病(HCM)患者中很常见,但遗传变异与 AF 之间的关系尚未得到明确界定。描述 HCM 的遗传亚型及其与 AF 的关联可能有助于改善个性化医疗。我们旨在研究 HCM 患者中肌节基因突变与 AF 事件之间的关系。
方法和结果 来自多国肌节性人类心肌病注册处的患者接受了 AF 事件的随访。那些在肌节基因中存在可能致病或致病性变异的患者被包括在内。每个研究地点通过审查病历和心电图来确定 AF 发生率。纳入了 1040 名成年 HCM 患者,这些患者无基线 AF,并且在肌球蛋白重链(MYH7)(n=296)、肌球蛋白结合蛋白 C(MYBPC3)(n=659)或细肌丝基因(n=85)中存在可能致病或致病性变异。与其他肌节基因变异的患者相比,在肌球蛋白重链基因变异的患者中,在首次就诊于肌节性人类心肌病注册处时年龄较轻,并且更有可能是先证者,而不是 MYBPC3 变异的先证者。在平均 7.2 年的随访期间,发生了 198 例 AF 事件。在调整年龄、性别、先证者状态、左心房大小、最大壁厚度和峰值压力梯度后,在 MYH7 中存在可能致病或致病性突变的患者的 AF 发生率最高(危险比,1.7;95%CI,1.1-2.6;P=0.009)。
结论 在平均 7.2 年的随访期间,19%的肌节突变 HCM 患者新发 AF。与其他肌节基因相比,MYH7 中存在可能致病或致病性变异的患者发生 AF 的发生率更高,独立于临床和超声心动图因素。